Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12552289 | 0.88 | LMNA (0.39) | LMNASMN1; SMN2TSHRGLAUSP2 | |
| SCHEMBL12552290 | 0.83 | — | — | |
| SCHEMBL13447330 | 0.81 | SMN1; SMN2 (0.41) | LMNASMN1; SMN2TSHRGLAUSP2 | |
| SCHEMBL12552202 | 0.81 | LMNA (0.40) | LMNASMN1; SMN2TSHRGLAUSP2 | |
| SCHEMBL559663 | 0.79 | SMN1; SMN2 (0.40) | LMNASMN1; SMN2TSHRGLAUSP2 | |
| SCHEMBL1385291 | 0.76 | SMN1; SMN2 (0.43) | LMNASMN1; SMN2TSHRGLAUSP2 | |
| SCHEMBL1385293 | 0.76 | SMN1; SMN2 (0.43) | LMNASMN1; SMN2TSHRGLAUSP2 | |
| SCHEMBL12552235 | 0.76 | LMNA (0.42) | LMNASMN1; SMN2TSHRGLAUSP2 | |
| SCHEMBL10842286 | 0.72 | HDAC8 (0.57) | LMNASMN1; SMN2TSHRGLAUSP2 | |
| SCHEMBL13412492 | 0.72 | LMNA (0.42) | LMNASMN1; SMN2TSHRGLAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150112051-A1 | CONSTRUCTION OF CELL PENETRATING NUCLEIC ACIDS | Panzner, Steffen | 2015-04-23 | — | — | US | disclosed |
| US-8957191-B2 | Nucleic acid comprising zwitterionic nucleotides | STEFFEN PANZNER (DE) | 2015-02-17 | — | — | US | disclosed |
| US-20110137019-A1 | NUCLEIC ACID COMPRISING ZWITTERIONIC NUCLEOTIDES | BIONTECH PROTEIN THERAPEUTICS GMBH (DE) | 2011-06-09 | — | — | US | disclosed |
| WO-2010004054-A2 | CONSTRUCTION OF CELL PENETRATING NUCLEIC ACIDS | NOVOSOM AG (DE) | 2010-01-14 | — | — | WO | disclosed |
| EP-2143726-A1 | Nucleic acid comprising zwitterionic nucleotides | Novosom AG (DE) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137019-A1 | NUCLEIC ACID COMPRISING ZWITTERIONIC NUCLEOTIDES | NSUN3, NCL, NUDT1 | LMNA 271/4885SMN1; SMN2 4195/4885TSHR 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.